Literature DB >> 12794751

Breast cell invasive potential relates to the myoepithelial phenotype.

Linda A Gordon1, Kellie T Mulligan, Helen Maxwell-Jones, Matthew Adams, Rosemary A Walker, J Louise Jones.   

Abstract

On the basis of marker profile, the majority of breast carcinomas are thought to be derived from luminal epithelial cells; however, a subgroup of tumours with more mesenchymal characteristics are associated with a worse prognosis. The hypothesis of our study is that some breast carcinomas exhibit myoepithelial rather than pure mesenchymal differentiation and that acquisition of myoepithelial characteristics confers an aggressive phenotype. Pure luminal epithelial cells and fibroblasts are readily distinguished by many markers but distinguishing between myoepithelial and fibroblast cell lineages is more problematic. The markers found to be most discriminating in our study were CK14, alpha6beta4 integrin and the myoepithelial-associated desmosomal cadherin DSg3. These markers were applied to a series of breast cell lines and purified normal breast cell populations and the expression profile related to in vitro invasive behaviour. This demonstrated that expression of one or more myoepithelial markers by tumour cells (MDA MB 231, MDA MB 468, MDA MB 436) was associated with a high invasive capacity compared with cells with a pure luminal phenotype (MCF-7, T47D, ZR75). To address why myoepithelial characteristics are associated with higher invasion, the in vitro behaviour of normal myoepithelial cells and two other nontumourigenic breast cell lines (MCF-10A, HBL100) was also analysed. Primary myoepithelial cells from normal human breast exhibit a high invasive capacity when grown at low density, suggesting that invasive capacity is part of the myoepithelial phenotype. In keeping with this, both nontumourigenic cell lines exhibited features of the myoepithelial phenotype and a high invasive capacity. These results suggest that tumours that exhibit a myoepithelial phenotype may be clinically more aggressive because a high invasive capacity is intrinsic to the myoepithelial phenotype. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12794751     DOI: 10.1002/ijc.11172

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  52 in total

1.  Promoter Methylation Modulates Indoleamine 2,3-Dioxygenase 1 Induction by Activated T Cells in Human Breast Cancers.

Authors:  Satish K Noonepalle; Franklin Gu; Eun-Joon Lee; Jeong-Hyeon Choi; Qimei Han; Jaejik Kim; Maria Ouzounova; Austin Y Shull; Lirong Pei; Pei-Yin Hsu; Ravindra Kolhe; Fang Shi; Jiseok Choi; Katie Chiou; Tim H M Huang; Hasan Korkaya; Libin Deng; Hong-Bo Xin; Shuang Huang; Muthusamy Thangaraju; Arun Sreekumar; Stefan Ambs; Shou-Ching Tang; David H Munn; Huidong Shi
Journal:  Cancer Immunol Res       Date:  2017-03-06       Impact factor: 11.151

Review 2.  Triple-negative breast cancer: disease entity or title of convenience?

Authors:  Lisa Carey; Eric Winer; Giuseppe Viale; David Cameron; Luca Gianni
Journal:  Nat Rev Clin Oncol       Date:  2010-09-28       Impact factor: 66.675

3.  Myoepithelial and luminal breast cancer cells exhibit different responses to all-trans retinoic acid.

Authors:  Damián E Berardi; Carolina Flumian; Paola B Campodónico; Alejandro J Urtreger; María I Diaz Bessone; Andrea N Motter; Elisa D Bal de Kier Joffé; Eduardo F Farias; Laura B Todaro
Journal:  Cell Oncol (Dordr)       Date:  2015-06-05       Impact factor: 6.730

4.  Mutation of a single allele of the cancer susceptibility gene BRCA1 leads to genomic instability in human breast epithelial cells.

Authors:  Hiroyuki Konishi; Morassa Mohseni; Akina Tamaki; Joseph P Garay; Sarah Croessmann; Sivasundaram Karnan; Akinobu Ota; Hong Yuen Wong; Yuko Konishi; Bedri Karakas; Khola Tahir; Abde M Abukhdeir; John P Gustin; Justin Cidado; Grace M Wang; David Cosgrove; Rory Cochran; Danijela Jelovac; Michaela J Higgins; Sabrina Arena; Lauren Hawkins; Josh Lauring; Amy L Gross; Christopher M Heaphy; Yositaka Hosokawa; Edward Gabrielson; Alan K Meeker; Kala Visvanathan; Pedram Argani; Kurtis E Bachman; Ben Ho Park
Journal:  Proc Natl Acad Sci U S A       Date:  2011-10-10       Impact factor: 11.205

5.  Analysis of microtubule growth dynamics arising from altered actin network structure and contractility in breast tumor cells.

Authors:  Eleanor C Ory; Lekhana Bhandary; Amanda E Boggs; Kristi R Chakrabarti; Joshua Parker; Wolfgang Losert; Stuart S Martin
Journal:  Phys Biol       Date:  2017-04-20       Impact factor: 2.583

6.  Collective invasion in breast cancer requires a conserved basal epithelial program.

Authors:  Kevin J Cheung; Edward Gabrielson; Zena Werb; Andrew J Ewald
Journal:  Cell       Date:  2013-12-12       Impact factor: 41.582

7.  A Peptide mimicking a region in proliferating cell nuclear antigen specific to key protein interactions is cytotoxic to breast cancer.

Authors:  Shanna J Smith; Long Gu; Elizabeth A Phipps; Lacey E Dobrolecki; Karla S Mabrey; Pattie Gulley; Kelsey L Dillehay; Zhongyun Dong; Gregg B Fields; Yun-Ru Chen; David Ann; Robert J Hickey; Linda H Malkas
Journal:  Mol Pharmacol       Date:  2014-12-05       Impact factor: 4.436

8.  Potential Indexing of the Invasiveness of Breast Cancer Cells by Mitochondrial Redox Ratios.

Authors:  Nannan Sun; He N Xu; Qingming Luo; Lin Z Li
Journal:  Adv Exp Med Biol       Date:  2016       Impact factor: 2.622

9.  Association of invasion-promoting tenascin-C additional domains with breast cancers in young women.

Authors:  David S Guttery; Rachael A Hancox; Kellie T Mulligan; Simon Hughes; Sinead M Lambe; J Howard Pringle; Rosemary A Walker; J Louise Jones; Jacqueline A Shaw
Journal:  Breast Cancer Res       Date:  2010-08-02       Impact factor: 6.466

10.  Characterization of breast precancerous lesions and myoepithelial hyperplasia in sclerosing adenosis with apocrine metaplasia.

Authors:  Julio E Celis; José M A Moreira; Irina Gromova; Teresa Cabezón; Pavel Gromov; Tao Shen; Vera Timmermans; Fritz Rank
Journal:  Mol Oncol       Date:  2007-03-14       Impact factor: 6.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.